Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Geron Corporation

Geron is engaged in the development of innovative medicines for myeloid hematologic malignancies. The company focuses on research and development, particularly in telomerase inhibition.

COM:GERON

Geron

Last Close

4.02

22/11 21:00

Market Cap

2.73B

Beta: -

Volume Today

6.85M

Avg: -